aTyr Pharma, Inc.
ATYR
$0.58
$0.034.86%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -96.39% | -32.82% | |||
| Gross Profit | 96.39% | 32.82% | |||
| SG&A Expenses | 0.34% | 5.48% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -4.85% | -22.71% | |||
| Operating Income | 4.85% | 22.71% | |||
| Income Before Tax | 4.47% | 22.72% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 4.47% | 22.72% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 0.00% | 0.00% | |||
| Net Income | 4.47% | 22.72% | |||
| EBIT | 4.85% | 22.71% | |||
| EBITDA | 4.98% | 22.94% | |||
| EPS Basic | 4.54% | 22.74% | |||
| Normalized Basic EPS | 4.51% | 22.70% | |||
| EPS Diluted | 4.54% | 22.74% | |||
| Normalized Diluted EPS | 4.51% | 22.70% | |||
| Average Basic Shares Outstanding | 0.03% | 0.03% | |||
| Average Diluted Shares Outstanding | 0.03% | 0.03% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||